– Life Sciences- Biotechnology Novartis to Get Expedited FDA Review of Secondary Progressive Multiple Sclerosis Drug

Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities for patients with SPMS ~

https://www.equities.com/news/novartis-to-get-expedited-fda-review-of-secondary-progressive-multiple-sclerosis-drug

This is good news if you have Secondary Progressive MS. I believe this would be the first medication approved for that type of MS. Research is paying off.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s